CIA
BMRN icon

Caerus Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Caerus Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$277K Sell
4,905
-5,331
-52% -$311K 0.12% 187
2025
Q4 		$608K Buy
10,236
+278
+3% +$15.1K 0.2% 115
2025
Q3 		$539K Buy
+9,958
New +$569K 0.22% 105

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caerus Investment Advisors's BMRN Position: Q1 2026 in Review

Caerus Investment Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 52% in Q1 2026, selling an estimated $311K and leaving 4,905 shares worth $277K. The position accounts for 0.12% of the portfolio, ranked #187.

Caerus Investment Advisors first reported a position in BMRN in Q3 2025 and has held it in 3 quarters since. The position peaked at $608K in Q4 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Caerus Investment Advisors held 4,905 shares of BioMarin Pharmaceuticals worth $277K as of Q1 2026.
  • Caerus Investment Advisors sold 5,331 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $311K.
  • BioMarin Pharmaceuticals made up 0.12% of Caerus Investment Advisors's portfolio in Q1 2026, its #187 holding.
  • Caerus Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Caerus Investment Advisors's BioMarin Pharmaceuticals position peaked at $608K in Q4 2025.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Caerus Investment Advisors's 13F filing for Q1 2026, filed 1 Jun 2026.